Navigation Links
Noninvasive diagnostics may offer alternative to liver biopsy for assessing liver fibrosis
Date:6/2/2011

Patients who are evaluated for liver diseases such as hepatitis C (HCV) are typically recommended for liver biopsy to determine the extent of disease progression. For patients who question whether less invasive testing is available, clinicians now have alternatives options to consider. Elastography and serum markers are two such diagnostic options reviewed in an editorial published in the June issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

Epidemiological studies report that approximately 150,000 individuals in the U.S. are diagnosed with chronic liver disease each year, and nearly 20% of these cases have cirrhosis at initial presentation. Complications from cirrhosis are determined by the extent and progression of fibrosis or scaring of the liver. Liver fibrosis, however, is not a linear process, but one that fluctuates with the influences of age, sex, race, alcohol exposure and obesity.

Liver biopsy remains the gold standard for determining activity and stage of fibrosis. However, this procedure has inherent limitations that include risk of pain or bleeding, inaccurate staging from sampling error, and variability of biopsy interpretation. With the increase in availability of sophisticated laboratory blood testing, the use of diagnostic liver biopsy is on the decline. "The drawbacks to liver biopsy have prompted researchers to investigate alternative, noninvasive markers for determining the severity of liver disease," said Dr. Jayant Talwalkar of the Mayo Clinic in Rochester, MN and editorial co-author.

Noninvasive screening with serum markers, or indicators in the blood, can identify patients at risk for liver fibrosis. Fibrotest, an indirect serum marker panel, is the most widely used and validated serum marker panel used worldwide. A number of studies have confirmed this panel to be reliable in detecting stage 4 fibrosis (cirrhosis) in patients with chronic HCV. Additional studies are underway to analyze its viability in hepatitis B, alcoholic liver disease, and nonalcoholic fatty liver disease.

Imaging techniques such as ultrasound-based transient elastography (TE) and magnetic resonance elastography (MRE) are noninvasive procedures that measure liver stiffness. Prior studies have found TE to be up to 90% accurate in diagnosing cirrhosis, and 70%-80% accurate in detecting stage 2 to stage 4 fibrosis. Evaluations of MRE have shown up to 85% accuracy for detecting intermediate to severe fibrosis (F2-F4). Currently only MRE is approved for use in the U.S.

"Noninvasive diagnostics are more advantageous to the patient as there are no serious side effects and they may be more cost effective when compared to liver biopsy although this remains to be determined," Dr. Talwalkar concluded. "Fibrotest or elastography imaging are helpful to confirm cirrhosis or minimal to no fibrosis. Liver biopsy may still be necessary to determine stage of fibrosis in those patients where noninvasive techniques were indeterminate."


'/>"/>

Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Mayo Clinic reports new findings on noninvasive test for pancreatic cancer
2. GEN reports on novel noninvasive tests for early cancer detection
3. Noninvasive extenders are better than surgery for men who want a longer penis
4. Noninvasive Test May Identify Down Syndrome Early On
5. Noninvasive test for trisomy 21 closer at hand
6. Noninvasive Glaucoma Test Might Speed Up Detection
7. Noninvasive brain stimulation helps improve motor function in stroke patients
8. Noninvasive Test for Colon Cancer Shows Promise in Early Trial
9. Prediction tool helps estimate local recurrence in patients with noninvasive breast cancer
10. Noninvasive combination technique may reduce number of breast biopsies
11. New research shows innovative respiratory stress test can quickly detect significant coronary artery disease in a noninvasive setting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... The ... its fully redesigned website, which launched October 17, 2016, features comprehensive information regarding ... and easy-to-navigate layout. Visitors and patients can discover the latest clinical dermatology treatments ...
(Date:12/7/2016)... , ... December 07, 2016 , ... Delete® - Tattoo ... Time For The Holiday Party Season. Save Up To 33% Off Botox® and Juvederm® ... is providing the Phoenix Valley with Delightful Deals on Botox® and Juvederm® ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live From won ... year’s best in pioneering, inventive, and ultimately successful projects undertaken by the media ...
(Date:12/7/2016)... ... December 07, 2016 , ... "ProBrand Flip allows FCPX editors to create ... Austin - CEO of Pixel Film Studios. , ProBrand Flip includes 30 flip book ... Editors can select from a variety of flip book animations. In Addition, users can ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... its newest portable bioelectronic medicine device WellnessPro Plus for consumers and healthcare ... enhances the WellnessPro platform by expanding the treatment modalities available in a ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... 7, 2016  The Corporate Whistleblower Center ... call them anytime at 866-714-6466 if they possess proof ... more drugs. Aside from the innocent patients frequently being the ... because often-times these practices target Medicare recipients or the elderly. ... ...
(Date:12/7/2016)... READING, Mass. , Dec. 7, 2016 /PRNewswire/ ... and Trace Network for connecting the Life Sciences ... the global marketplace, today announced that Tjoapack has ... European pharmaceutical manufacturing customers comply with the rapidly ... Chain Security Act (DSCSA) in 2017 and the ...
(Date:12/7/2016)... 7, 2016 According to responses from U.S. oncologists ... (38%) of patients with non-small cell lung cancer (NSCLC), treatment ... (EGFR) genetic mutation status. The findings of the survey were ... #6067 #P3.02b ) at the 2016 World Conference on ... The survey results revealed an overall high rate ...
Breaking Medicine Technology: